Page 3 - Matthias Eiber News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7 3

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3 - read this article along with other careers information, tips and advice on BioSpace

Siemens healthineers biographDavid gaudenScintomics gmbSiemens healthineersMatthias eiberBruce spottiswoodeTechnical university of munichNuclear medicineDepartment of nuclear medicineClinical applications researchBracco groupBlue earth diagnosticsUniversity hospitalTechnical universityProstate specific membrane antigen targetedEarth diagnostics

ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress

ITM to Host Symposium on Actinium-225 Targeted Radionuclide Therapy and to Present Phase III COMPOSE Trial Design at the Theranostics World Congress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Communicationsjulia hofmann susanne karlssonNeil quigleyMethodsneil quigleySteffen schusterSebastian marxUdoj vetterMatthias eiberClinic for nuclear medicineUniversity hospital essenTechnical university of munichGarching munichdistrict courtSymposium programDeutsche bank freiburgTheranostics world congressPolyclinic for nuclear medicineWall street

PSMA PET Validates EAU Classification System to Determine Risk of Prostate Cancer Recurrence

Reston, VA-New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk classification system that groups prostate

Ann arborUnited statesUniversity of california los angelesUniversity of california san franciscoSan franciscoWolfgang fendlerBenjaminl vigliantiOsama mohamadAndrea farolfiWesleyr armstrongJustin ferdinandusLos angelesKen hermannJohannes czerninMiguelh pampaloniPeter jh scott

Prostatectomy Without Biopsy Is Feasible, Says German Study

Imaging techniques might be accurate enough to replace biopsies for prostate cancer in select patients.

United statesUniversity of chicagoTelix pharmaScott eggenerMatthias eiberValentinh meissnerTechnical university of munichInternational society of urological pathologyProgenics pharmaceuticalsTechnical universityProstate imaging reportingData systemInternational societyUrological pathologyMedscape medicalBlue earth diagnostics

Tool helps predicts who will respond best to targeted prostate cancer therapy

New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows UCLA Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady | July 8, 2021 A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.

United statesBaden wübergWolfgang fendlerWesley armstrongMichael hofmanRouzbeh esfandiariUwe haberkornEbrahim delpassandMatthew rettigClemens kratochwilKen herrmannJohannes czerninDavid elashoffTristan groganShahneen sandhuBoris hadaschik